VPC
MPLT

Vestal Point Capital’s MapLight Therapeutics MPLT Stock Holding History

Vestal Point Capital’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-420,000
Closed -$8.54M – 99
2026
Q1 		$8.54M Buy
420,000
+35,000
+9% +$626K 0.24% 67
2025
Q4 		$6.76M Buy
+385,000
New +$6.45M 0.23% 57

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vestal Point Capital's MPLT Position: Q2 2026 in Review

Vestal Point Capital sold out of MapLight Therapeutics (MPLT) in Q2 2026, closing a stake of 420,000 shares — an estimated $8.54M sold.

Vestal Point Capital first reported a position in MPLT in Q4 2025 and held it in 2 quarters. The position peaked at $8.54M in Q1 2026. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Vestal Point Capital reported no remaining MapLight Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 420,000 MapLight Therapeutics shares in Q2 2026, an estimated $8.54M.
  • Vestal Point Capital first reported a position in MapLight Therapeutics in Q4 2025 and held it in 2 quarters.
  • Vestal Point Capital's MapLight Therapeutics position peaked at $8.54M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.